Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 5 Next >
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces change in R&D leadership
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Continued strong growth in Q3 with key regulatory milestones achieved
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.